Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial

What this study found

Green cardamom supplementation showed overall beneficial effects on glucose indices, lipids, and liver status. Compared with placebo, it significantly increased irisin, HDL-C, and QUICKI and decreased fasting insulin, HOMA-IR, and triglycerides, with time-by-treatment interaction p-values < 0.001 for fasting insulin, HOMA-IR, QUICKI, HDL-C, and irisin, and 0.005 for triglycerides. LDL-C decreased in unadjusted analyses but only showed a trend after adjustment; fasting glucose, total cholesterol, and BMI did not change significantly. The authors concluded that cardamom may improve fatty liver…

Study & population

Double-blind randomized placebo-controlled clinical trial in overweight or obese adults with non-alcoholic fatty liver disease diagnosed by ultrasonography.

Intervention

Green cardamom was given orally as 3 g/day of whole Elettaria cardamomum powder in capsules, taken as two 500 mg capsules with each meal for 3 months.

Key limitation

The trial was relatively small, single-center, and short at 3 months, which limits confidence in durability and generalizability.

View full study detailsView sourceOpen PDF